ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Vitamin D supplements, sleep could help manage pain

Bacopa: The Herb That May Increase Your Brain Power

Lilac Oil: More Than Just for Fragrance

Eat More Yogurt and Avoid Osteoporosis

Safflower: An Economically Important Herb That Can Benefit Humans and Animals Alike

What Is Bilberry Good For?

Coffee, herbal tea may help prevent liver fibrosis

Crafty Uses for Carrot Seed Oil

Resveratrol Improves Arteries

Higher omega 3 levels linked to improved brain blood flow

 
Print Page
Email Article

Stanford study shows drug for treating type-2 diabetes may limit heart disease risk

  [ 31 votes ]   [ Discuss This Article ]
www.ProHealth.com • June 17, 2003


STANFORD, Calif. - A drug used to treat high blood sugar in people with type-2 diabetes also may lower the risk of cardiovascular disease, according to research at Stanford University Medical Center.

If larger studies confirm these results, the drug, called rosiglitazone, may be a good choice for patients with type 2-diabetes who require additional medications to prevent heart attacks.
"If you have a diabetes drug that lowers not only blood sugar but also the risk for heart disease, that might be favorable for the patient with diabetes who already takes as many as eight to 12 pills a day," said James W. Chu, MD, director of the Diabetes Center at Santa Clara Valley Medical Center and adjunct clinical investigator at Stanford. Chu and Gerald Reaven, MD, emeritus professor of medicine at the Stanford School of Medicine, will present results from their study June 17 at the annual meeting of the American Diabetes Association in New Orleans.

In type-2 diabetes, the body's tissues are resistant to or don't efficiently respond to insulin's signal to take up sugar from the blood. If the body doesn't overcome this resistance by making extra insulin, blood sugar will rise, leading to diabetes. First described by Reaven, insulin resistance goes hand-in-hand with a group of health problems including obesity, high blood pressure, type-2 diabetes, increased inflammation and heart disease.

To control blood sugar, people with type-2 diabetes take drugs such as rosiglitazone. But as a result of insulin resistance, they are also at risk of heart attacks, requiring additional medications to treat high blood pressure and cholesterol and to prevent arteries from clogging.

Recent studies have suggested that increased inflammation linked to insulin resistance may contribute to an elevated risk of heart disease. "Theoretically, giving a drug that inhibits the inflammatory response might be useful for preventing cardiovascular disease," Reaven said. Based on earlier work showing that rosiglitazone decreases insulin resistance and lowers blood sugar, Chu and Reaven proposed that the drug also may reduce inflammation.

They tested this idea by giving rosiglitazone to 29 people, 14 of whom had type-2 diabetes and 15 who were insulin-resistant but didn't have diabetes. They followed the participants, recording levels of insulin, blood sugar and other blood components that indicate abnormal metabolism or increased risk for heart disease.

After three months of taking rosiglitazone, the study participants had significantly lower levels of certain molecules that indicate the presence of inflammation. Of these molecules, C-reactive protein is a powerful predictor of cardiovascular risk. The other molecules - plasminogen activator inhibitor-1, E-selectin, L-selectin and P-selectin - are often elevated in people with metabolic and cardiovascular disease.

The finding that these inflammatory molecules decreased in patients taking rosiglitazone hints that the drug also may lower the risk of heart disease, but Reaven urges caution in interpreting these results.

"The fact that the phenomenon takes place doesn't mean the end point will change. You still need a much larger study that measures cardiovascular disease in people taking the drug," Reaven said. He also noted that people who are insulin-resistant but do not yet have diabetes should take diabetes medications such as rosiglitazone only as participants in medical research.

Chu said this study could help doctors decide how to distinguish between the five classes of oral diabetes drugs currently available for type-2 diabetes. "Because most people with diabetes die of heart disease, a drug that potentially can treat multiple facets of the insulin-resistance syndrome is exciting," Chu said.



Other Stanford researchers who contributed to the study include Fahim Abbasi, MD, research associate; Cynthia Lamendola, research coordinator; Tracey McLaughlin, MD, clinical instructor; and Philip Tsao, MD, assistant professor of medicine.

Print media contact: Michelle Brandt, 650-723-0272 mbrandt@stanford.edu
Broadcast media contact: Neale Mulligan, 650-724-2454 nealem@stanford.edu

Embargoed for release until: June 17, 2003, at 6 a.m. Pacific time to coincide with a presentation at the annual meeting of the American Diabetes Association

Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.



Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra EPA  - Fish Oil FibroSleep™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products


Article Comments



Be the first to comment on this article!

Post a Comment


 
NAD+ Ignite with Niagen

Featured Products

Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Herbal Rescue for High Blood Sugar Herbal Rescue for High Blood Sugar
Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial
D-ficient? Health Risks You Need to Know About D-ficient? Health Risks You Need to Know About
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!
Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed Fight Inflammation and Promote Cognitive Health with High-OPC Grape Seed

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map